RPUSD4 (RNA Pseudouridine Synthase D4) encodes a mitochondrial pseudouridine synthase that catalyzes the isomerization of uridine to pseudouridine (ψ) in mitochondrial rRNA and tRNA molecules[1]. This enzymatic conversion, termed pseudouridylation, is the most abundant RNA modification in nature and is essential for mitochondrial translation fidelity, ribosome assembly, and cellular respiration. RPUSD4 is highly expressed in tissues with high metabolic demand, including brain, heart, and skeletal muscle, where mitochondrial dysfunction has profound pathological consequences[2].
The RPUSD4 gene is located on chromosome 9q34.3 and encodes a protein of 461 amino acids. The enzyme localizes to the mitochondrial matrix where it modifies specific uridine residues in 12S and 16S rRNA, as well as several mitochondrial tRNAs. Loss-of-function mutations in RPUSD4 lead to mitochondrial translation defects, reduced oxidative phosphorylation (OXPHOS), and progressive neurological deterioration[3].
RPUSD4 belongs to the pseudouridine synthase family (Pus enzymes) conserved from bacteria to humans:
| Species | RPUSD4 Homolog | Identity | Mitochondrial |
|---|---|---|---|
| E. coli | TruA | 35% | No |
| S. cerevisiae | Pus1p | 38% | Yes |
| D. melanogaster | TfAP | 42% | Yes |
| Danio rerio | rpsd4 | 68% | Yes |
| Mus musculus | Rpusd4 | 82% | Yes |
| Homo sapiens | RPUSD4 | 100% | Yes |
The conservation of catalytic aspartate residues (Asp73, Asp75, Asp77) across species underscores the essential nature of pseudouridylation for mitochondrial function.
RPUSD4 expression varies across brain regions, correlating with vulnerability to mitochondrial disease:
| Brain Region | RPUSD4 Expression | Vulnerability |
|---|---|---|
| Cerebral cortex | High | Moderate |
| Hippocampus | High | Severe |
| Cerebellar Purkinje cells | High | Moderate |
| Substantia nigra | Moderate-High | Severe (PD) |
| Dorsal motor root ganglia | High | Severe |
| Spinal cord motor neurons | Very High | Severe |
| Property | Value |
|---|---|
| Gene Symbol | RPUSD4 |
| Full Name | RNA Pseudouridine Synthase D4 |
| Chromosomal Location | 9q34.3 |
| NCBI Gene ID | 285456 |
| Ensembl ID | ENSG00000156575 |
| UniProt ID | Q8N5K2 |
| OMIM | 614739 |
| Gene Type | Protein coding |
| Property | Value |
|---|---|
| Protein Name | RPUSD4 (mitochondrial pseudouridine synthase D4) |
| Molecular Weight | 52 kDa |
| Amino Acids | 461 |
| Subcellular Localization | Mitochondrial matrix |
| Protein Family | Pseudouridine synthase (Pus) |
RPUSD4 catalyzes the pseudouridylation reaction through a unique base-flipping mechanism[4]:
The catalytic residues (Asp73-Asp-X-Asp-Arg motif) coordinate water molecules and facilitate the isomerization through a covalent intermediate mechanism.
RPUSD4 modifies specific uridines in mitochondrial RNAs:
| Substrate | Position | Modification |
|---|---|---|
| 12S rRNA | U1369 | ψ1369 |
| 12S rRNA | U1397 | ψ1397 |
| 16S rRNA | Various | Multiple |
| tRNA^Phe | U27 | ψ27 |
| tRNA^Leu | U34 | ψ34 |
Mitochondrial dysfunction is a hallmark of many neurodegenerative diseases. RPUSD4 plays a critical role in maintaining mitochondrial homeostasis:
RPUSD4 dysfunction may contribute to AD pathogenesis through[5]:
In PD, RPUSD4 may affect[6]:
RPUSD4 and related mitochondrial factors are implicated in ALS[7]:
| Variant | Effect | Phenotype |
|---|---|---|
| c.457C>T (p.R153X) | Nonsense | Severe mitochondrial disease |
| c.623G>A (p.G208E) | Missense | Variable |
| c.829A>G (p.K277R) | Missense | Moderate |
| c.1042C>T (p.R348W) | Missense | Severe |
| Approach | Mechanism | Stage |
|---|---|---|
| Gene therapy | Wildtype RPUSD4 delivery | Preclinical |
| Small molecules | Enhance pseudouridylation | Research |
| Mitochondrial cofactors | Boost OXPHOS | Clinical |
| RNA modifiers | Improve mitochondrial translation | Research |
RPUSD4 contains several functional domains:
| Domain | Residues | Function |
|---|---|---|
| N-terminal targeting | 1-25 | Mitochondrial import |
| Catalytic core | 26-380 | Pseudouridylation |
| RNA-binding | 150-250 | Substrate recognition |
| C-terminal dimerization | 381-461 | Homodimer formation |
The catalytic mechanism relies on:
RPUSD4 is expressed in:
RPUSD4 activity may serve as a biomarker:
| Biomarker | Disease | Change |
|---|---|---|
| RPUSD4 activity | AD | Reduced 30-50% |
| RPUSD4 activity | PD | Reduced 20-40% |
| RPUSD4 activity | ALS | Reduced 40-60% |
| Mitochondrial pseudouridine | Leigh syndrome | Severe reduction |
| Protein | Interaction Type | Function |
|---|---|---|
| MRP-L10 | Structural | Mitochondrial ribosome |
| MRP-L18 | Binding | rRNA modification |
| MT-TU | Substrate | tRNA pseudouridylation |
| TFAM | Co-regulation | Mitochondrial transcription |
Wu G, Xiao M, Yang C, et al. RPUSD4 and the mitochondrial RNA processing landscape. RNA Biol. 2023. ↩︎
Chen C, Huang C, Li Z, et al. RNA modifications in mitochondrial function and disease. Nat Rev Dis Primers. 2024. ↩︎
Hayashi M, et al. RPUSD4 deficiency leads to mitochondrial dysfunction. Nat Commun. 2019. ↩︎
Asano K, et al. Mitochondrial RNA pseudouridylation is essential for translational fidelity. J Biol Chem. 2022. ↩︎
Abbasi M, Moeini P, Hosseini M, et al. The role of RNA modifications in neurodegeneration. J Mol Neurosci. 2023. ↩︎
Jonkhout N, Tran J, Viero G, et al. The epitranscriptome in neurological disease. Nat Rev Neurol. 2023. ↩︎
Iommi M, et al. RNA binding proteins in ALS. Brain. 2020. ↩︎